spacer
home > ict > autumn 2016 > keeping tabs
PUBLICATIONS
International Clinical Trials

Keeping Tabs

Expiring patents, greater competition and price pressure, together with high regulatory requirements through ever stringent legislation describe the current situation in the pharmaceutical industry.

According to the trend analysis ‘Clinical trial management systems: Business success with modern solutions’ by Pierre Audoin Consultants (PAC), pharma companies are confronted with the challenge of filling their R&D pipelines in order to bring new medicines and active ingredients to the market in short cycles. At the same time, it is necessary to optimise all processes – from development to the production of new medicines – to reduce both cost and risk. In the trend study, PAC points out the seven greatest hurdles in clinical trial management:
  1. Obtaining governmental approvals
  2. Selection and management of sites
  3. Project management
  4. Project performance and control
  5. Time management
  6. Reporting
  7. Management of data and documents


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Jan Klint Nielsen is Senior Project Manager and CTMS Community Manager at BSI, and has been with the company since 2007. He has many years of experience as a project manager of large international projects, and as a department manager of major development and maintenance teams.
spacer
Jan Klint Nielsen
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

ERT’s At-Home Cardiac Safety Assessment Ensures Clinical Trial Continuity

PHILADELPHIA – March 30, 2020 – ERT, a global data and technology company that captures critical endpoint data while minimizing uncertainty and risk in clinical trials, today announced a cardiac safety solution that helps biopharmaceutical researchers continue important clinical trials during current global ‘stay home’ mandates. The solution enables clinician-administered ECG readings ─ using ERT’s provisioned, FDA-cleared devices or other investigative site–owned equipment ─ to evaluate the safety of new vaccines and medical treatments from patients’ homes.
More info >>

White Papers

Backward Thinking: The Reverse Engineering of A Pressurized Metered Dose Inhaler

Development of a generic equivalent to a current marketed pressurized metered dose inhaler (pMDI) product brings immense challenges. Thorough analysis is critical to gain a comprehensive understanding of the physical attributes and pharmaceutical performance of the reference marketed product. Many factors need to be assessed, understood and combined in order to successfully develop a generic pMDI which will meet the regulatory and quality requirements as an equivalent product in the anticipated target market. Significant information about the reference marketed product can be obtained from a thorough review of published literature, specifically the Summary of Product Characteristics (SPC) and Patient Information Leaflet (PIL). Additionally, baselining the reference marketed product for pharmaceutical performance offers a working target specification for in-vitro correlation. It will ensure the smoothest possible path to commercialization and maximize return on investment. In addition, baselining of the reference marketed product is done to understand batch-to-batch variability and product performance over the stated shelf life to establish targets for critical quality attributes (CQAs), which can be applied to the generic equivalent pMDI.
More info >>

 
Industry Events

Clinical Operations in Oncology Trials West Coast

17-18 November 2020, Hilton San Francisco Airport Bayfront

Clinical Operations in Oncology Trials West Coast will be returning this April for another 2 day event full of thought-provoking presentations, discussions and roundtables. This years' conference highlights include the high-level, interactive immuno-oncology discussion panel where specialists from Shasta Bio Ventures, Abbvie and BeiGene shared their top tips on how to run successful and impactful immuno-oncology studies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement